News
Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...
First-line treatment includes trastuzumab (Herceptin, Genentech) plus chemotherapy. Some patients also receive pembrolizumab (Keytruda, Merck). However, “most patients experience disease ...
1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information ...
I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...
Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...
17d
MedPage Today on MSNT-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal CancerPatients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...
13d
SurvivorNet on MSNAn Exciting Option For Difficult-To-Treat HER2+ Gastric Cancer: What New Data Means For PatientsFor the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...
Advancements in Genomics and AI Propel Patient-Centric Therapies Across Key Regions The global personalized medicine market ...
Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results